Analysts are concerned that the weak cold and flu season in the season could hit sales of some of Reckitt’s big brands such as Strepsils, Lemsip and Nurofen.
Those worries knocked 4% off the share price on Wednesday, and Jefferies thinks there is “still further to go”.
But the analysts’ biggest issue is with the workplace culture, especially after the “surprise retirement” of chief executive Rakesh Kapoor who is due to leave by the end of the year.
“The surprise retirement of CEO Rakesh Kapoor crystallises long-brewing anxieties around RB's predicament,” read a note to clients.
“There are strong runners and riders for the role aplenty. But this is a challenge
beyond mere fresh legs. The unique RB pay for performance model, so powerful for so long, is now under pressure, laying bare the fact that RB has the weakest culture and workstyle ratings in the peer group.”
The analysts argue that the merger of GlaxoSmithKline PLC’s (LON:GSK) and Pfizer’s consumer health businesses – Reckitt was interested in Pfizer’s assets – might have been “the straw that broke Kapoor’s back”.
“Not only does it stalemate RB strategically, it also cuts off a vital source of fresh innovation. That leaves RB's Health Relief portfolio reliant on under-pressure Mucinex and a yeoman infantry of Nurofen, Strepsils and Gaviscon fast running out of marching space.”
Given its various fears, Jefferies has downgraded the FTSE 100 group to ‘underperform’ from hold, while it has also slashed its price target to 5,000p from 6,800p previously.
Reckitt shares fell 3% on Thursday morning to 5,611p, making it the biggest faller on London’s blue-chip index.